ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO734

Differences in the Prevalence of Metabolic Syndrome and Its Components among Ethnic Minorities with CKD

Session Information

Category: Diabetes

  • 502 Diabetes Mellitus and Obesity: Clinical


  • Lorch, Robert, Baylor College of Medicine, Houston, Texas, United States
  • Niu, Jingbo, Baylor College of Medicine, Houston, Texas, United States
  • Walther, Carl P., Baylor College of Medicine, Houston, Texas, United States
  • Raghavan, Rajeev, Baylor College of Medicine, Houston, Texas, United States
  • Winkelmayer, Wolfgang C., Baylor College of Medicine, Houston, Texas, United States
  • Navaneethan, Sankar D., Baylor College of Medicine, Houston, Texas, United States

Metabolic syndrome (MetS) and chronic kidney disease (CKD) are common among ethnic minorities. Whether clustering of various metabolic risk factors occurs irrespective of race is unclear. Herein, we studied whether the prevalence of MetS and its components differed between African Americans (AAs) and Hispanics with CKD.


We identified patients with stage 3 and 4 CKD (based on 15≤ eGFR <60 ml/min/1.73 m2) who were followed during 2006-2016 in the Harris Health System, a safety-net health system in Houston, TX. Demographics, comorbid conditions, and laboratory data were extracted from electronic medical records. MetS was defined as the presence of three or more of the following components: body mass index (BMI) ≥30 kg/m2, serum triglyceride level≥150 mg/dl, HDL≤50 mg/dl in women and ≤40 mg/dl in men, hypertension (BP>130/85 mmHg or on antihypertensive medications), and impaired glucose metabolism (presence of diabetes, use of oral hypoglycemics, or blood glucose level≥200 mg/dl). Age- and sex-adjusted prevalence ratios were calculated using modified Poisson regression with robust variance.


Of 8664 patients with CKD Stage 3 or 4, 6954 (80%) had MetS. The prevalence of MetS was highest among Hispanics (87%), followed by non-Hispanic whites (85%), AA (74%), and Asian Americans (71%). While comparing MetS and its components between AAs and Hispanics, we noted higher prevalence for high triglycerides, low HDL levels, and diabetes, but lower prevalence of obesity among Hispanics than AAs (Table 1).


MetS and its components were highly prevalent in patients with CKD receiving care in a Texan safety-net system, particularly among Hispanics and non-Hispanic Whites. Differences in the prevalences of MetS-defining components between AAs and Hispanics suggest that interventions targeting MetS might need to be tailored based on race.


  • NIDDK Support